Paradromics gets FDA nod for broader BCI device compatibility

Paradromics has received approval from the US FDA to broaden the range of personal computing devices compatible with its investigational BCI system. The FDA approval will enable the BCI platform to support more internet-connected personal devices including laptops, tablets and phones. Paradromics intends to implement the changes through Convey, which translates decoded neural signals into communication and digital control. Credit: Gorodenkoff/Shutterstock.com. Neurotech company Paradromics has received approval from the US Food and Drug Administration (FDA) to broaden the range of personal computing devices compatible with its investigational brain-computer interface (BCI) system. The authorisation pertains to the company’s ongoing Connect-One Early…

Source: Medical Device Network